Why rare diseases are an important medical and social issue

The Lancet

Volumn 371, Issue 9629, 2008, Pages 2039-2041

  Schieppati, Arrigo ^a   Henter, Jan Inge ^b   Daina, Erica ^a   Aperia, Anita ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTISM; BRUGADA SYNDROME; CONGENITAL DIAPHRAGM HERNIA; DYSTONIA; ERYTHROPOIETIC PROTOPORPHYRIA; ESOPHAGUS ATRESIA; FALLOT TETRALOGY; GREAT VESSELS TRANSPOSITION; GUILLAIN BARRE SYNDROME; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MARFAN SYNDROME; MEDICAL SOCIETY; MELANOMA; MULTIPLE MYELOMA; NARCOLEPSY; NEUROFIBROMATOSIS; NONHODGKIN LYMPHOMA; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RARE DISEASE; RETINITIS PIGMENTOSA; REVIEW; SCLERODERMA; WORLD HEALTH ORGANIZATION;

EID: 44849143056     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60872-7     Document Type: Review

References (14)

1. van Weely S., and Leufkens H. Orphan diseases. Background paper. In: priority medicines for Europe and the world. A public health approach to innovation. http://mednet3.who.int/prioritymeds/report/index.htm#c (accessed July, 2006).
2. US Food and Drug Administration. Orphan Drug Act, Pub L. No. 97-414, 96 Stat. 2049 (1982). http://www.fda.gov/orphan/oda.htm (accessed May, 2008).
3. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev1.htm (accessed July, 2006).
4. OrphanXchange. About orphan drugs. http://www.orphanxchange.org/OXC/cgi-bin/oxc_about_drug.php (accessed July, 2006).
5. Wastfelt M., Fadeel B., and Henter J.-I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 260 (2006) 1-10
6. United States Department of Health and Human Services, Public Health Service, and Office of the Assistant Secretary for Health. Report of the National Commission on Orphan Diseases (1989), Office of the Assistant Secretary for Health, Rockville, MD
7. WHO. International Classification of Diseases. 10th revision. http://www.who.int/classifications/apps/icd/icd10online/ (accessed July, 2006).
8. Orphanet. Rare diseases in numbers: preliminary report from an on going bibliographic study initiated by Eurordis in partnership with Orphanet. http://www.orpha.net/actor/Orphanews/2005/doc/Rare_Diseases_in_Numbers.pdf (accessed July, 2006).
9. Weiner D. Pediatrics: inborn errors of metabolism. http://www.emedicine.com/emerg/topic768.htm (accessed July, 2006).
10. Dionisi-Vici C., Rizzo C., Burlina A., et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 140 (2002) 321-327
11. Eurordis. EurordisCare2: survey of diagnostic delays, 8 diseases, Europe. http://www.eurordis.org/big_article.php3?id_article=454 (accessed July, 2006).
12. The Independent Expert Group. Ethical, legal and social aspects of genetic testing: research, development and clinical applications. Brussels (2004). http://ec.europa.eu.research/conferences/2004/genetic/report_en.htm (accessed July, 2006).
13. Overview of current Centres of Reference on rare diseases in the EU. Report to the High Level Group on Health Services and Medical Care, and Annexes (September 2005). http://ec.europa.eu/health/ph_information/implement/wp/morbidity/keydocs_morbidity_en.htm (accessed July, 2006).
14. Haffner M. Adopting orphan drugs: two dozen years of treating rare diseases. N Engl J Med 354 (2006) 445-447